Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 9/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8618855 | 0.87 | MAOB (0.45) | EPAS1HTR1AHTR1DHTR1BAR | |
| SCHEMBL2473229 | 0.83 | AR (0.56) | AR | |
| SCHEMBL3682584 | 0.78 | TRPV4 (0.42) | SLC22A12TRPV4EPAS1HTR1AHTR1D | |
| SCHEMBL28364202 | 0.76 | TRPV4 (0.48) | TRPV4AR | |
| SCHEMBL4842836 | 0.76 | AR (0.46) | SLC22A12EPAS1AR | |
| SCHEMBL9454958 | 0.76 | AR (0.46) | SLC22A12AR | |
| SCHEMBL3958603 | 0.75 | EPAS1 (0.41) | SLC22A12EPAS1AR | |
| SCHEMBL10535321 | 0.75 | TRPV4 (0.55) | SLC22A12TRPV4AR | |
| SCHEMBL20719139 | 0.75 | PDE4A (0.40) | HTR1AHTR1DHTR1BAR | |
| SCHEMBL31435300 | 0.75 | EPAS1 (0.40) | SLC22A12EPAS1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | MARTINEZ-PEREZ JOSE ANTONIO | 2010-04-15 | — | — | US | disclosed |
| EP-2166003-A1 | Excitatory amino acid receptor antagonists | Eli Lilly & Company (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7601738-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| CN-1980918-A | Substituted indazoles, compositions containing them, preparation and use | AVENTIS PHARMA SA (FR) | 2007-06-13 | — | — | CN | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | ARNOLD MACKLIN B | 2006-05-11 | — | — | US | disclosed |
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY | 2004-07-15 | — | — | US | disclosed |
| EP-1368032-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003024453-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | SLC22A12 807/4885TRPV4 371/4885EPAS1 1945/4885 |
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, GRIN1 | SLC22A12 807/4885TRPV4 371/4885EPAS1 1945/4885 |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | SLC22A12 807/4885TRPV4 371/4885EPAS1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.